The implicit reason of secondary osteoporosis: real clinical case

This article presents a non-standard clinical case of non-obvious causes of secondary osteoporosis in the routine practice of an outpatient and inpatient endocrinologist. This work demonstrates a rather rare situation, including the identification of atypical clinical manifestations of osteoporosis in a patient, namely the presence of a young man with complaints of general weakness, severe pain in the spine, forcing daily use of non-steroidal anti-inflammatory drugs, decreased motor activity, and laboratory indicators such as hypercalcemia, hypercalciuria against the background of reference values of parathyroid hormone, hyperproteinemia and increased ESR. Taking into account the clinical picture described above, an integral part of a further correct diagnostic search is the exclusion of endocrine diseases that cause a decrease in bone mineral density. In parallel, the initiated prescription of pathogenetically based treatment of secondary osteoporosis is an important component of this disease. The use of such a multidisciplinary approach led to timely verification of the underlying oncohematological disease and routing the patient to a specialized hospital and made it possible to prevent irreversible changes associated with a critical decrease in bone mineral density and improve the patient’s quality of life.

1. Belaya ZE, Belova KYu, Biryukova EV, et al. Yakushevskaya O.V. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47. (In Russ.). doi: https://doi.org/10.14341/osteo12930

2. Сamacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016. Endocr Pract. 2016;22(S4):1-42. doi: https://doi.org/10.4158/EP161435.GL

3. Kanis JA, Cooper C, Rizzoli R, Reginster J-Y. Scientific advisory board of the european society for clinical and Economic Aspects of Osteoporosis (ESCEO) and the committees of scientific advisors and National societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44. doi: https://doi.org/10.1007/s00198-018-4704-5.

4. Сosman F, de Beur SJ, LeBoff MS, et al. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. doi: https://doi.org/10.1007/s00198-014-2794-2

5. Gaudio A, Xourafa A, Rapisarda R, et al. Hematological diseases and osteoporosis. Int J Mol Sci. 2020;21(10):3538. doi: https://doi.org/10.3390/ijms21103538

6. Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2010;(109):283-291. doi: https://doi.org/10.1002/jcb.22403

7. Bouvard B, Royer M, Chappard D, et al. Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Jt Bone Spine. 2010;77(2):120-124. doi: https://doi.org/10.1016/j.jbspin.2009.12.002

8. Koski A-M, Sikio A, Forslund T. Teriparatide treatment complicated by malignant myeloma. Case Reports. 2010;2010:bcr0120102681. doi: https://doi.org/10.1136/bcr.01.2010.2681

9. Forslund T, Koski A-M, Koistinen A, Sikiö A. Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence. Clin Med Case Reports. 2008;(1):119-122. doi: https://doi.org/10.4137/CCRep.S1026

10. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6(1):12-16. doi: https://doi.org/10.1007/s11914-008-0003-y

11. Barry CM. Who sharpened Occam’s Razor? Irish Philosophy; 2014.